Events

EIT Food's 1st Northern European “4 per 1000” Regional Meeting
JUN
Tue
06
JUN
Wed
07
JUN
Thu
08

This was 2 years ago

Location

Hilton Helsinki - Kalastajantorppa

Hilton Helsinki Kalastajantorppa, Kalastajatorpantie 1, Helsinki, 00330 (Finland)
Programmes
Missions

The above mentioned event is organised by Baltic Sea Action Group in collaboration with the "4 per 1000" Initiative. Join the Northern European colleagues in Helsinki, Finland for new perspectives and new partners in scaling up regenerative agriculture! 

This above metioned meeting aims to connects real-world farming, policy, research, and business.

The participation is free of charge, however, the organisers reserve the right to charge no-shows with the costs incurred (approx. 150 € per day).

More detailed information, the full agenda with the speakers and the possibility to register can be found by clicking here.

Source: EIT page - Events

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.